Leadership Corner Articles
Patient safety is an endemic concern — one that must be addressed by many stakeholders, including government agencies, manufacturers, healthcare providers and others, all working collectively to safely care for patients.
With the growing demand for biologics, biosimilars promise additional treatment options, but their introduction is not without challenges.
On average, only 25 new experimental drugs were approved by the FDA’s Center for Drug Evaluation and Research (CDER) every year during the past decade. Taking more than 10 years to go from testing to treatment, the healing properties of these drugs help countless numbers of patients, sometimes providing life-changing and lifesaving results.
A “vaccination gap” has resulted in fewer children receiving the recommended immunizations, and diseases that were once considered all but eliminated are reemerging.
FFF Enterprises takes a “safety first” approach when it comes to business best practices for distributing fragile biologics and transport-sensitive vaccines.
As president and CEO of TraceLink,Inc., Shabbir Dahod leads a visionary team that helps companies meet the complex requirements of the Drug Supply Chain Security Act.
In this annual plasma-themed issue of BioSupply Trends Quarterly, we take a critical look at the current plasma market, especially issues of supply and demand.
As we peer into the not-too-distant future, is it possible that some of the treatments that seem so innovative today will also be looked back upon as unsophisticated?
From a bi-weekly newsletter to an award-winning quarterly magazine, BioSupply Trends Quarterly has grown to be a timely, trustworthy source for biopharmaceutical news.
As CEO of FFF Enterprises, Inc., Patrick Schmidt takes pride in his company’s success in helping to secure the specialty biopharmaceuticals marketplace over the past 26 years.
A deeper look at major risks in the healthcare industry, including lack of preventative care, inadequate care, adverse drug reactions and counterfeit drugs.
As U.S. Director of Sales & Marketing, Influenza, Chris Woolway is creating strategic partnerships to address industry challenges.